UX in ops, designing car-free cities, and an MVP checklist.
Each week our design editors curate the most notable, interesting, and important material they come across. Below you’ll find their recent selections. You can get these and more in our weekly design newsletter.
Tweet of the week
— Jeff Sussna (@jeffsussna) February 10, 2015
The O'Reilly Radar Podcast: Martin Charlier on industrial and interaction design, reflecting societal values, and unified visions.
Editor’s note: Martin Charlier will present a session, Prototyping User Experiences for Connected Products, at the O’Reilly Solid Conference, June 23 to 25, 2015, in San Francisco. For more on the program and information on registration, visit the Solid website.
Designing for the Internet of Things is requiring designers and engineers to expand the boundaries of their traditionally defined roles. In this Radar Podcast episode, O’Reilly’s Mary Treseler sat down with Martin Charlier, an independent design consultant and co-founder at Rain Cloud, to discuss the future of interfaces and the increasing need to merge industrial and interaction design in era of the Internet of Things.
Charlier stressed the importance of embracing the symbiotic nature of interaction design and service design:
“How I got into Internet of Things is interesting. My degree from Ravensbourne was in a very progressive design course that looked at product interaction and service design as one course. For us, it was pretty natural to think of product or services in a very open way. Whether they are connected or not connected didn’t really matter too much because it was basically understanding that technology is there to build almost anything. It’s really about how you design with that mind.
“When I was working in industrial design, it became really clear for me how important that is. Specifically, I remember one project working on a built-in oven … In this project, we specifically couldn’t change how you would interact with it. The user interface was already defined, and our task was to define how it looked. It became clear to me that I don’t want to exclude any one area, and it feels really unnatural to design a product but only worry about what it looks like and let somebody else worry about how it’s operated, or vice versa. Products in today’s world, especially, need to be thought about from all of these angles. You can’t really design a coffee maker anymore without thinking about the service that it might plug into or the systems that it connects to. You have to think about all of these things at the same time.”
From data-driven government to our age of intelligence, here are key insights from Strata + Hadoop World in San Jose, CA, 2015.
Experts from across the big data world came together for Strata + Hadoop World in San Jose, CA, 2015. We’ve gathered insights from the event below.
U.S. chief data scientist
With a special recorded introduction from President Barack Obama, DJ Patil talks about his new role as the U.S. government’s first ever chief data scientist, the nature of the U.S.’s emerging data-driven government, and defines his mission in leading the data-driven initiative:
“Responsibly unleash the power of data for the benefit of the American public and maximize the nation’s return on its investment in data.”
The O'Reilly Radar Podcast: Balaji Srinivasan on the bigger picture of bitcoin, liquid markets, and the future of regulation.
The promise of bitcoin and blockchain extends well beyond its potential disruption as a currency. In this Radar Podcast episode, Balaji Srinivasan, a general partner at Andreessen Horowitz, explains how bitcoin is an enabling technology and why it’s like the Internet, in that “bitcoin will do for value transfer what the Internet did for communication — make it programmable.” I met up with Srinivasan at our recent O’Reilly Radar Summit: Bitcoin & the Blockchain, where he was speaking — you can see his talk, and all the others from the event, in the complete video compilation now available.
The bigger picture of bitcoin
More than just a digital currency, bitcoin can serve as an instigator for new markets. Srinivasan explained the potential for everything to become a liquid market:
“Bitcoin is a platform for programmable money, programmable interchange, or anything of value. That’s very general. People have probably heard at this point about how you can use a blockchain to trade — in theory — stocks, or houses, or other kinds of things, but programmable value transfer is even bigger than just trading things which we know already exist.
“One analogy I would give is in 1988, it was not possible to find information on anything instantly. Today, most of the time it is. From your iPhone or your Android phone, you can google pretty much anything. In the same way, I think what bitcoin is going to mean, is markets in everything. That is, everything will have a price on it — everything will be a liquid market. You’ll be able to buy and sell almost anything. Where today the fixed costs of setting up such a market is too high for anything other than things that are fairly valuable, tomorrow it’ll be possible for even images or things you would not even think of normally buying and selling.”
The O'Reilly Radar Podcast: DJ Kleinbaum on lab automation, virtual lab services, and tackling the challenges of reproducibility.
The convergence of software and hardware, and the growing ubiquitousness of the Internet of Things is affecting industry across the board, and biotech labs are no exception. For this Radar Podcast episode, I chatted with DJ Kleinbaum, co-founder of Emerald Therapeutics, about lab automation, the launch of Emerald Cloud Laboratory, and the problem of reproducibility.
Kleinbaum and his co-founder Brian Frezza started Emerald Therapeutics to research cures for persistent viral infections. They didn’t set out to spin up a second company, but their efforts to automate their own lab processes proved so fruitful, they decided to launch a virtual lab-as-a-service business, Emerald Cloud Laboratory. Kleinbaum explained:
“When Brian and I started the company right out of graduate school, we had this platform anti-viral technology, which the company is still working on, but because we were two freshly minted nobody Ph.D.s, we were not going to be able to raise the traditional $20 or $30 million that platform plays raise in the biotech space.
“We knew that we had to be much more efficient with the money we were able to raise. Brian and I both have backgrounds in computer science. So, from the beginning, we were trying to automate every experiment that our scientists ran, such that every experiment was just push a button, walk away. It was all done with process automation and robotics. That way, our scientists would be able to be much more efficient than your average bench chemist or biologist at a biotech company.
“After building that system internally for three years, we looked at it and realized that every aspect of a life sciences laboratory had been encapsulated in both hardware and software, and that that was too valuable a tool to just keep internally at Emerald for our own research efforts. Around this time last year, we decided that we wanted to offer that as a service, that other scientists, companies, and researchers could use to run their experiments as well.” Read more…
The O'Reilly Radar Podcast: Tim Gardner on the synthetic biology landscape, lab automation, and the problem of reproducibility.
Editor’s note: this podcast is part of our investigation into synthetic biology and bioengineering. For more on these topics, download a free copy of the new edition of BioCoder, our quarterly publication covering the biological revolution. Free downloads for all past editions are also available.
Tim Gardner, founder of Riffyn, has recently been working with the Synthetic Biology Working Group of the European Commission Scientific Committees to define synthetic biology, assess the risk assessment methodologies, and then describe research areas. I caught up with Gardner for this Radar Podcast episode to talk about the synthetic biology landscape and issues in research and experimentation that he’s addressing at Riffyn.
Defining synthetic biology
Among the areas of investigation discussed at the EU’s Synthetic Biology Working Group was defining synthetic biology. The official definition reads: “SynBio is the application of science, technology and engineering to facilitate and accelerate the design, manufacture and/or modification of genetic materials in living organisms.” Gardner talked about the significance of the definition:
“The operative part there is the ‘design, manufacture, modification of genetic materials in living organisms.’ Biotechnologies that don’t involve genetic manipulation would not be considered synthetic biology, and more or less anything else that is manipulating genetic materials in living organisms is included. That’s important because it gets rid of this semantic debate of, ‘this is synthetic biology, that’s synthetic biology, this isn’t, that’s not,’ that often crops up when you have, say, a protein engineer talking to someone else who is working on gene circuits, and someone will claim the protein engineer is not a synthetic biologist because they’re not working with parts libraries or modularity or whatnot, and the boundaries between the two are almost indistinguishable from a practical standpoint. We’ve wrapped it all together and said, ‘It basically advances in the capabilities of genetic engineering. That’s what synthetic biology is.'”